These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27846756)

  • 1. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.
    Yamazaki H; Hirano F; Takeuchi T; Amano K; Kikuchi J; Kihara M; Yokoyama W; Sugihara T; Nagasaka K; Hagiyama H; Nonomura Y; Sakai R; Tanaka M; Koike R; Nanki T; Kohsaka H; Miyasaka N; Harigai M
    Mod Rheumatol; 2017 Sep; 27(5):787-794. PubMed ID: 27846756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.
    Hirano F; Yokoyama W; Yamazaki H; Amano K; Kawakami A; Hayashi T; Tamura N; Yasuda S; Dobashi H; Fujii T; Ito S; Kaneko Y; Matsui T; Okuda Y; Saito K; Suzuki F; Yoshimi R; Sakai R; Koike R; Kohsaka H; Miyasaka N; Harigai M;
    Mod Rheumatol; 2017 Sep; 27(5):811-819. PubMed ID: 27919205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
    Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
    Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
    Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
    Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
    Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study.
    Tanaka Y; Kubo S; Yamanaka H; Amano K; Hirata S; Tanaka E; Nagasawa H; Yasuoka H; Takeuchi T
    Mod Rheumatol; 2014 Sep; 24(5):754-62. PubMed ID: 25036232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.
    Tanaka Y; Yamanaka H; Saito K; Iwata S; Miyagawa I; Seto Y; Momohara S; Nagasawa H; Kameda H; Kaneko Y; Izumi K; Amano K; Takeuchi T
    Mod Rheumatol; 2012 Apr; 22(2):186-94. PubMed ID: 21901357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.
    Kubo S; Saito K; Hirata S; Fukuyo S; Yamaoka K; Sawamukai N; Nawata M; Iwata S; Mizuno Y; Tanaka Y
    Mod Rheumatol; 2014 Jan; 24(1):42-51. PubMed ID: 24261758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for structural remission using abatacept: Results from the ABROAD study.
    Murakami K; Sekiguchi M; Hirata S; Fujii T; Matsui K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    Mod Rheumatol; 2019 May; 29(3):406-412. PubMed ID: 29807445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
    Kida D; Takahashi N; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Ando M; Kuwatsuka Y; Tanaka E; Yasuoka H; Kaneko Y; Hirata S; Murakami K; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
    Sci Rep; 2020 Nov; 10(1):19717. PubMed ID: 33184461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.
    Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N
    Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
    Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
    J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.
    Ahmad HA; Baker JF; Østergaard M; Emery P; Durez P; Ye J; Banerjee S; Conaghan PG
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):959-964. PubMed ID: 31549793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.